What insurance policy changes affect code G30.8?

There are 3 tracked policy changes affecting code G30.8, including updates from Independence Blue Cross, Humana. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code G30.8?

Payers that have issued tracked updates for code G30.8 include: Independence Blue Cross, Humana.

How do I get notified when code G30.8 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code G30.8. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code G30.8?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

G30.8 Insurance Policy Changes

ICD-10 G30.8 is officially defined as "Other Alzheimer's disease." code G30.8 is referenced in 3 tracked payer policy changes from Independence Blue Cross and Humana. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code G30.8 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Independence Blue Cross · Effective Jan 1, 2026Medium impact
MA08.151e, Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease
Independence Blue Cross updated MA08.151e to clarify coverage for monoclonal antibodies directed against amyloid (aducanumab, lecanemab, donanemab) for Alzheimer's disease treatment. These drugs remain experimental/investigational and NOT covered except through Medicare's Coverage with Evidence Development (CED) program for patients enrolled in approved clinical studies. Billing teams must ensure claims for these medications are only submitted when patients are actively enrolled in CED clinical trials.
Humana · Effective Oct 1, 2025Medium impact
Antipsychotic Utilization Program (New)
Humana Louisiana Medicaid has implemented a new antipsychotic utilization program requiring prior authorization for antipsychotic medications prescribed to patients with documented dementia diagnoses. The program includes strict age-based criteria and specific compendia-supported indications for approval.
Independence Blue Cross · Identified Jun 19, 2026Low impact
MA08.151d, Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease
Independence Blue Cross Medicare Advantage policy MA08.151d for amyloid-directed monoclonal antibodies (aducanumab, lecanemab, donanemab) has been superseded by version MA08.151e. The policy reiterates that these drugs remain experimental/investigational and NOT covered except through CMS Coverage with Evidence Development (CED) programs for Medicare Advantage members enrolled in approved clinical trials. A new HCPCS code (J0175 for donanemab-azbt) was added in July 2024, and FDA approval of donanemab (Kisunla) in July 2024 is documented.

Watch G30.8

Get one email when a payer policy names G30.8, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

MA08.151e, Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease

Antipsychotic Utilization Program (New)

MA08.151d, Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease

What insurance policy changes affect code G30.8?

Which payers have updated policy for code G30.8?

How do I get notified when code G30.8 policy changes?

Why do payers change policies for code G30.8?